Study Evaluating Genotypes Using Lucentis
NCT00474695 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 65
Last updated 2015-02-11
Summary
The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms
Conditions
- Age-Related Maculopathy
Interventions
- DRUG
-
Lucentis
0.05 mg intravitreal injection
Sponsors & Collaborators
-
Genentech, Inc.
collaborator INDUSTRY - lead OTHER
Principal Investigators
-
Paul Bernstein, MD, PhD · University of Utah
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-05-31
- Primary Completion
- 2009-06-30
- Completion
- 2009-12-31
Countries
- United States
Study Locations
More Related Trials
-
Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
NCT01310686 ·Status: UNKNOWN
-
Evaluation of R:GEN as Intervention in Subjects With Early Stages of AMD for Safety and Exploratory Efficacy Outcomes
NCT04776031 ·Status: COMPLETED ·Phase: NA
-
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
NCT01089517 ·Status: COMPLETED ·Phase: PHASE2
-
A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration
NCT01678872 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
NCT01601483 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
NCT02543229 ·Status: COMPLETED ·Phase: PHASE1
-
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
NCT01255462 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients
NCT02296567 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting
NCT05266495 ·Status: TERMINATED
-
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
NCT03211234 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
NCT02599064 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
NCT06817343 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy
NCT06212297 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
NCT01339949 ·Status: WITHDRAWN ·Phase: NA
-
Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
NCT00527423 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
NCT03626636 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447980 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT04607148 ·Status: TERMINATED ·Phase: PHASE2
-
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT04615325 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT00447993 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease
NCT04311112 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration
NCT02127463 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
NCT01624636 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT02399072 ·Status: TERMINATED
-
Recurrent Neovascular Age-related Macular Degeneration After Therapy Suspension
NCT04659512 ·Status: COMPLETED